| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human; 1:1; loading ...; tbl 1
| Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher |
- immunohistochemistry; cat; 1:1; loading ...; tbl 2
| Dagher E, Royer V, Buchet P, Abadie J, Loussouarn D, Campone M, et al. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer. BMC Cancer. 2019;19:1267 pubmed publisher |
- immunocytochemistry; human; loading ...; fig 4a
| Espinoza Sánchez N, Enciso J, Pelayo R, Fuentes Panana E. An NF?B-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features. Oncotarget. 2018;9:26679-26700 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2e
| Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, et al. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Sci Rep. 2016;6:39557 pubmed publisher |
- immunohistochemistry - paraffin section; human; fig 1a
| Dobosz M, Haupt U, Scheuer W. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule. MAbs. 2017;9:140-153 pubmed publisher |
- immunohistochemistry; human; fig 1a
| Ladd B, Mazzola A, Bihani T, Lai Z, BRADFORD J, Collins M, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 2016;7:54120-54136 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 1a
| Shen F, Zhang Y, Jernigan D, Feng X, Yan J, Garcia F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016;14:518-27 pubmed publisher |
- western blot; cat; 1:20; fig 5b
| Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:60
| McBryan J, Fagan A, McCartan D, Bane F, Varešlija D, Cocchiglia S, et al. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clin Cancer Res. 2015;21:5371-9 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; tbl 4
| Figenschau S, Fismen S, Fenton K, Fenton C, Mortensen E. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer. 2015;15:101 pubmed publisher |
| Rikhi R, Wilson E, Déas O, Svalina M, Bial J, Mansoor A, et al. Murine model of hepatic breast cancer. Biochem Biophys Rep. 2016;8:1-5 pubmed publisher |
| Pinder S, Campbell A, Bartlett J, Marshall A, Allen D, Falzon M, et al. Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. Br J Cancer. 2017;116:859-863 pubmed publisher |
| Catalano O, Horn G, Signore A, Iannace C, Lepore M, Vangel M, et al. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer. 2017;116:893-902 pubmed publisher |
| Qi L, Zhou L, Lu M, Yuan K, Li Z, Wu G, et al. Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips. Biochem Biophys Res Commun. 2017;484:248-254 pubmed publisher |
